1 |
NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993;270:83-90.
|
2 |
Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
DOI
|
3 |
Sanchez-Cruz JJ, Cabrera-Leon A, Martín-Morales A, et al. Male erectile dysfunction and health related quality of life. Eur Urol 2003;44:245-53.
DOI
|
4 |
Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4.
DOI
|
5 |
Ministry of Food and Drug Safety. Webzine. 2012;Mar+Apr:15-18. Available from: http://www.mfds.go.kr/webzine/201204/ibook_12mar.jsp.
|
6 |
Yang SK. KSSMA eradication campaign for counterfeit PDE5I. Kor J Androl 18th conference 2012.
|
7 |
Kao SL, Chan CL, Tan B, et al. An unusual outbreak of hypoglycemia. N Engl J Med 2009;360:734-6.
DOI
|
8 |
Department of Health of the Government of the Hong Kong Special Administrative Region. Public urged not to consume capsules for treating sexual dysfunction with undeclared drug. Press Release 2008.
|
9 |
Ministry of Food and Drug Safety. Regulation on potential misuse and abuse drugs. 2014.2.12.
|
10 |
Ministry of Food and Drug Safety. Drug Safety Use Manual 22. Oral Phosphodiesterase Type 5 Inhibitors. 2013.9.4.
|
11 |
Kim MS, Myung SC, Kim SC. Perceptions of Erectile Dysfunction Treatment of Patients Visiting a University Hospital in the Era of Multiple Oral Agents. Kor J Androl 2006;24:18-22.
|
12 |
Jackson G, Montorsi P, Cheitlin MD. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology. 2006;68:47-60.
DOI
|
13 |
Carson CC, Burnett AL, Levine LA, et al. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology. 2002;60:12-27.
|
14 |
Banks I, Kirby M, Marfatia A, et al. Assessment, in a General Population of men, of Men's Interaction With the Healthcare System to Obtain Phosphodiesterase Type 5 Inhibitors. Joint Congress of the European and International Societies for Sexual Medicine, December 7-11, Brussels, Belgium, 2008.
|
15 |
Schnetzler G, Banks I, Kirby M, et al. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J Sex Med 2010;7:1237-46.
DOI
|
16 |
Korean Society for Sexual Medicine and Andrology. Fake Phosphodiesterase Type 5 Inhibitors Status. 2012;10:26-29.
|
17 |
Kim SC. Sexual Attitude and Perception on Erectile Dysfunction Treatment among Patients with Erectile Dysfunction and the Patients' Spouses. Korean J Androl 2009;27:1-9.
|
18 |
Micromedex (http://www.micromedexsolutions.com/micromedex2/librarian/)
|
19 |
Yang CS, Kim SC. The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors. Korean J Urol 2006;47:272-7.
DOI
|
20 |
Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med 2012;9:265-70.
DOI
|
21 |
Ministry of Food and Drug Safety. Press Release. 2014.7.31. Available at: http://www.mfds.go.kr/index.do?mid=675&seq=24693.
|